Children with cancer are at high risk of infection because of chemotherapeutic treatment, subsequent immune suppression as well as the common use of central venous access devices (Bradford et al., 2020;Green & Aarons, 2011;Lehrnbecher et al., 2012). An estimated 30% of all cases of chemotherapy-induced neutropenia in children with cancer are associated with fever, which may be the only sign of underlying severe infection, a potentially lethal complication of treatment (Agyeman et al., 2011;Hausler, 2020). Children can deteriorate rapidly, and delayed treatment is associated with increased intensive care admissions and death (Fletcher et al., 2013;Salstrom et al., 2015). For these reasons, the universally accepted gold standard management for both adults and children is prompt assessment and administration of empiric antibiotic, ideally within 60 minutes of presentation. These recommendations are detailed in Clinical Practice Guidelines, consensus statements that aggregate evidence to assist in clinical management decisions (De Naurois et al., 2010;